Corvus Pharmaceuticals (CRVS)
(Delayed Data from NSDQ)
$1.45 USD
-0.03 (-2.03%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.44 -0.01 (-0.69%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth F Momentum D VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CRVS 1.45 -0.03(-2.03%)
Will CRVS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CRVS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRVS
Here's Why Corvus (CRVS) is Poised for a Turnaround After Losing -25% in 4 Weeks
Down -18.35% in 4 Weeks, Here's Why Corvus (CRVS) Looks Ripe for a Turnaround
CRVS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Corvus (CRVS) Upgraded to Buy: What Does It Mean for the Stock?
Corvus' (CRVS) Lymphoma Drug Gets Orphan Status, Stock Up
What Makes Corvus (CRVS) a New Buy Stock
Other News for CRVS
Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
12 Health Care Stocks Moving In Tuesday's After-Market Session
Corvus initiates placebo-controlled phase 1 soquelitinib clinical trial
Hold Rating Maintained for Corvus Pharmaceuticals Amid Clinical Delays and Financing Concerns
Corvus Pharmaceuticals: Insider Ownership Raises Power Concentration Concerns